St. Jude/SRI International
This article was originally published in The Gray Sheet
Executive Summary
Collaborating on development of St. Jude's BioXenoGraft, a bioprosthesis "which would have improved durability over conventional tissue valve products" and avoid the need for anticoagulants associated with mechanical valves, St. Jude says. SRI International, a nonprofit corporation chartered by the state of California, will apply its "expertise in implantable bioprosthetic devices" to the development of the product. The work will complement a project between St. Jude and Advanced Tissue Sciences to use ATS' tissue engineering technology to develop tissue heart valves with improved biocompatibility and durability ("The Gray Sheet" Feb. 21, I&W-1)
You may also be interested in...
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.
GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows
A major shift from unfettered coverage to prior authorizations was recorded by MMIT over the past year for the leading GLP-1/GIP agonist diabetes drugs. Public interest in using the drugs off label for weight loss drove the change.